A Phase 3 Multi-center Randomized Double-blinded Study of MK-7684 with Pembrolizumab as a Co-formulation (MK-7684A) Versus Pembrolizumab Monotherapy as a First Line Treatment for Participants with PD-L1 Positive (TPS>=1%) Metastatic Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Metastatic Non-small Cell Lung Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Has a histologically or cytologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC). 2) Has measurable disease based on RECIST 1.1, as determined by the local site assessment. 3) Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy (documentation of the absence of tumor-activating EGFR mutations [eg,DEL19 or L858R], AND absence of ALK and ROS1 gene rearrangements).

You may not be eligible for this study if the following are true:

  • 1) Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. 2) Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. 3) Has received previous treatment with another agent targeting the TIGIT receptor pathway.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.